MBX Biosciences (MBX) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026MBX 4291 obesity program
Q4 unblinding of the phase I/IIa C1 cohort is the key near-term milestone; planned readouts cover 12-week weight loss and its trajectory, longitudinal GI tolerability, and PK.
C1 includes 30 subjects: 20 on active treatment and 10 on placebo; the expected PK profile includes a 26-day T-half Cmax, supporting once-monthly dosing.
Competitive 12-week weight-loss benchmark is 6%-8%, based on phase III data for tirzepatide and semaglutide; May’s blinded B1 data showed 7% aggregate weight lowering in six active and two placebo subjects.
May’s blinded B1 safety dataset showed one mild diarrhea case; the prodrug design targets a gradual 5-6-day rise to Cmax to potentially improve GI tolerability.
Phase IIb is planned for next year, assuming success, with multiple doses and schedules informed by the unblinded study; management expects the study’s totality of evidence to support moving into phase II.
Obesity portfolio and strategy
C2 started after C1 and is expected to inform phase II design; additional data flow and development plans were expected to be discussed later in Q4.
Management is working toward a commercially competitive single-injection device for a future phase III; vial and syringe are planned for phase IIb to avoid delaying its start.
Strategy is to demonstrate differentiation through phase I/IIa and phase IIb data, then seek a partner to support concurrent, multiple phase III studies.
MBX 6180 triple G preclinical data in non-human primates supported projection of a monthly dose; two other obesity assets are in IND-enabling studies, with potential future candidate nominations.
The platform is designed to engineer peptide release profiles from one hour to 1,000 hours; management cited a wide-open landscape for true once-monthly agents.
Canvuparatide and commercial plans
Twelve-month open-label extension data showed sustained clinical benefit for chronic hypoparathyroidism; phase III oPTimize recruitment remains on track for completion in H2 next year.
Patient and investigator engagement has been strong, with no observed impact from YORVIPATH on recruitment or timelines; the weekly administration drew interest.
Management plans to build a U.S. commercial organization and has begun pre-commercial work; it views the chronic hypoparathyroidism market as suitable for standalone commercialization.
YORVIPATH’s reported Q3 revenue run rate was ~$1.2 billion, with estimated market penetration of 5%-7%; management cited this as validation of unmet need and market potential.
Latest events from MBX Biosciences
- Canvuparatide advances in phase III as monthly obesity assets progress toward key data.MBX
3rd Annual Guggenheim Healthcare Innovation Conference - Canvuparatide Phase 3 began; $481.6M in liquidity supported runway into 2029.MBX
Q3 2026 - Advancing once-weekly and once-monthly peptide therapies with strong clinical and market momentum.MBX
Stifel 2026 Virtual Cardiometabolic Forum - Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027.MBX
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 net loss rose to $37.1M as R&D spending increased; cash reserves support operations into 2029.MBX
Q2 2026 - Advancing precision peptide therapies for endocrine and obesity indications with strong clinical momentum.MBX
Corporate presentation - Phase III for once-weekly canvuparatide starts Q3 2024, with major 2026 data and strong financials.MBX
Piper Sandler 37th Annual Healthcare Conference - Once-weekly canvuparatide showed durable efficacy and safety at one year, supporting Phase III advancement.MBX
Study result - All director and auditor proposals were approved by stockholders at the annual meeting.MBX
AGM 2026